Empagliflozin versus Sitagliptin as add-on dual therapy in Egyptian patients with type 2 diabetes inadequately controlled with Metformin: a 12-week randomized, open-label, parallel-group trial (vol 12, 104, 2023)

被引：0
|
作者：
Zakaraia, Haitham G. [1 ]
Salem, Heba F. [2 ]
Mostafa, Mostafa A. A. [3 ]
Ali, Ahmed M. [4 ]
Rabea, Hoda M. [5 ]
机构：
[1] Univ Sadat City, Fac Pharm, Clin Pharm Dept, POB 32897, Sadat City, Menoufia, Egypt
[2] Beni Suef Univ, Fac Pharm, Pharmaceut & Ind Pharm Dept, POB 62514, Bani Suwayf, Egypt
[3] October 6 Univ, Fac Med, Internal Med Dept, POB 12585, Giza, Egypt
[4] October 6 Univ, Fac Pharm, Clin Pharm Dept, POB 12585, Giza, Egypt
[5] Beni Suef Univ, Fac Pharm, Clin Pharm Dept, POB 62514, Bani Suwayf, Egypt
来源：
BENI-SUEF UNIVERSITY JOURNAL OF BASIC AND APPLIED SCIENCES | 2024年 / 13卷 / 01期
关键词：
D O I：
10.1186/s43088-024-00487-9
中图分类号：
O [数理科学和化学]; P [天文学、地球科学]; Q [生物科学]; N [自然科学总论];
学科分类号：
07 ; 0710 ; 09 ;
摘要：
引用
收藏
页数：1
相关论文
共 50 条
  • [31] Comparison Between Pioglitazone/Metformin Combination Therapy and Sitagliptin/Metformin Combination Therapy on the Efficacy in Chinese Type 2 Diabetic Adults Insufficiently Controlled with Metformin: Study Protocol of an Open-Label, Multicenter, Non-Inferiority Parallel-Group Randomized Controlled Trial
    Zhang, Fang
    Tang, Lizhi
    Li, Jing
    Yan, Zhe
    Li, Juan
    Tong, Nanwei
    DIABETES METABOLIC SYNDROME AND OBESITY, 2021, 14 : 1243 - 1252
  • [32] Efficacy and Tolerability of Initial Triple Combination Therapy with Metformin, Dapagliflozin, and Saxagliptin Compared with Conventional Stepwise Add-on Therapy in Drug-Naive Patients with Type 2 Diabetes-A Randomized, 104-Week, Open-Label, Active-Controlled Trial
    Kim, Nam Hoon
    Kim, Ji Yoon
    Moon, Jun Sung
    Lee, Yong-Ho
    Kwak, Soo Heon
    Lim, Soo
    Moon, Min Kyong
    Kim, Sin Gon
    DIABETES, 2023, 72
  • [33] Empagliflozin as Add-on to Metformin Plus Sulfonylurea in Patients With Type 2 Diabetes A 24-week, randomized, double-blind, placebo-controlled trial
    Haering, Hans-Ulrich
    Merker, Ludwig
    Seewaldt-Becker, Elke
    Weimer, Marc
    Meinicke, Thomas
    Woerle, Hans J.
    Broedl, Uli C.
    DIABETES CARE, 2013, 36 (11) : 3396 - 3404
  • [34] Efficacy and safety of combination therapy with vildagliptin and metformin versus metformin uptitration in Chinese patients with type 2 diabetes inadequately controlled with metformin monotherapy: a randomized, open-label, prospective study (VISION)
    Ji, L-N
    Pan, C-Y
    Lu, J-M
    Li, H.
    Zhu, D-L
    Li, Q.
    Li, Q-F
    Peng, Y-D
    Tian, H-M
    Yao, C.
    Zhao, Z-G
    Wang, L.
    Wang, B-H
    DIABETES OBESITY & METABOLISM, 2016, 18 (08): : 775 - 782
  • [35] Liraglutide Versus Sitagliptin in a 24-week, Multicenter, Open-label, Randomized, Parallel-group Study in Japanese Type 2 Diabetes Mellitus Patients Responding Inadequately to a Sulfonylurea and/or One or Two Other Oral Antidiabetic Drugs (JDDM 33)
    Yokoyama, Hiroki
    Hirao, Koichi
    Yamaguchi, Kohei
    Oishi, Mariko
    Lee, Gendai
    Yagi, Noriharu
    Takamura, Hiroshi
    Kashiwagi, Atsunori
    JAPANESE CLINICAL MEDICINE, 2014, 5 : 33 - 41
  • [36] Efficacy of polyethylene glycol loxenatide versus insulin glargine on glycemic control in patients with type 2 diabetes: a randomized, open-label, parallel-group trial
    Zhang, Shuo
    Zhang, Chuanyan
    Chen, Jingxian
    Deng, Feiying
    Wu, Zezhen
    Zhu, Dan
    Chen, Fengwu
    Duan, Yale
    Zhao, Yue
    Hou, Kaijian
    FRONTIERS IN PHARMACOLOGY, 2023, 14
  • [37] Remission effect of Canagliflozin in patients with newly diagnosed type 2 diabetes mellitus: a protocol for a multicenter, parallel-group, randomized, controlled, open-label trial
    Yang, Xue
    He, Zhiwei
    Yuan, Li
    Huang, Wenbin
    Li, Doudou
    Xiang, Pingping
    Chen, Yu
    Chen, Guofang
    Liu, Chao
    BMC ENDOCRINE DISORDERS, 2023, 23 (01)
  • [38] Remission effect of Canagliflozin in patients with newly diagnosed type 2 diabetes mellitus: a protocol for a multicenter, parallel-group, randomized, controlled, open-label trial
    Xue Yang
    Zhiwei He
    Li Yuan
    Wenbin Huang
    Doudou Li
    Pingping Xiang
    Yu Chen
    Guofang Chen
    Chao Liu
    BMC Endocrine Disorders, 23
  • [39] Dapagliflozin add-on to metformin in type 2 diabetes inadequately controlled with metformin: a randomized, double-blind, placebo-controlled 102-week trial (vol 11, pg 193, 2013)
    Bailey, Clifford J.
    Gross, Jorge L.
    Hennicken, Delphine
    Iqbal, Nayyar
    Mansfield, Traci A.
    List, James F.
    BMC MEDICINE, 2013, 11
  • [40] Comparison of empagliflozin and glimepiride as add-on to metformin in patients with type 2 diabetes: a 104-week randomised, active-controlled, double-blind, phase 3 trial
    Ridderstrale, Martin
    Andersen, Knut Robert
    Zeller, Cordula
    Kim, Gabriel
    Woerle, Hans J.
    Broedl, Uli C.
    LANCET DIABETES & ENDOCRINOLOGY, 2014, 2 (09): : 691 - 700
12345